Back to Search Start Over

Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes

Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes

Authors :
Ilenia Pepe
Salvatore Di Rosa
Gerald H. Tomkin
Manfredi Rizzo
Angelo Maria Patti
Gaetana Di Fede
Giovam Battista Rini
Maria Rosa Valerio
Rizzo, M
Tomkin, GH
Patti, AM
Pepe, I
Valerio, MR
Di Rosa, S
Rini, GB
Di Fede, G
Source :
Clinical Lipidology. 6:539-547
Publication Year :
2011
Publisher :
Informa UK Limited, 2011.

Abstract

Type 2 diabetes is associated with a cluster of inter-related plasma lipid and lipoprotein abnormalities, including reduced HDL-C, a predominance of small, dense LDL and elevated triglycerides. These abnormalities occur even in prediabetes, before blood sugars rise sufficiently in order to confirm a diagnosis of diabetes, and this transition phase incurs important cardiovascular risk. This is the rationale for paying attention to dyslipidemia through the use of the hypolipidemic, rather than hypoglycemic drugs only. A literature search (by Medline and Scopus) was performed. The authors also manually reviewed the references of selected articles for any pertinent material. Beyond the ‘quantity’ of LDL, several lipid-lowering agents and particularly statins, are only in part beneficial on the ‘quality’ of LDL, so that their net effect on small, dense LDL is moderate. Among hypoglycemic agents, insulin and metformin have shown a limited role on small, dense LDL, while pioglitazone is more beneficial. The effi...

Details

ISSN :
17584302 and 17584299
Volume :
6
Database :
OpenAIRE
Journal :
Clinical Lipidology
Accession number :
edsair.doi.dedup.....e2238ae640118c6b2e4c382d6023da4d
Full Text :
https://doi.org/10.2217/clp.11.46